Radiation plus chemo vs chemo alone for borderline resectable pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether giving targeted radiation therapy first, followed by a combination chemotherapy (NALIRIFOX), is better than chemotherapy alone for people with pancreatic cancer that is borderline resectable. The goal is to see if the radiation helps shrink the tumor enough to make surgery possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with a confirmed diagnosis of pancreatic cancer.
- The cancer is considered borderline resectable (meaning it might be removable with surgery after some shrinkage).
- You have not had any prior treatment for this cancer.
- You are generally active and able to do light work (ECOG 0-1).
- Your blood counts, liver, and kidney function are within a certain range (checked by your doctor).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving proton radiation and chemotherapy before surgery can shrink or control “borderline resectable” pancreatic cancer so it can be removed more effectively. It may help by improving treatment response while planning for surgery afterward.
This trial tests a combination of chemotherapy drugs (AG and FOLFIRINOX) with an immunotherapy drug (PD-L1 antibody) to shrink pancreatic tumors that are borderline resectable or locally advanced, making them removable by surgery. It's for people who haven't had any previous cancer treatment.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before and after surgery for people with pancreatic cancer that is at high risk of coming back but can still be surgically removed. The goal is to see if this treatment helps improve outcomes.
This trial tests whether adding the drug IBI343 to chemotherapy before surgery can help people with borderline resectable pancreatic cancer. It is for those whose tumors have a specific protein called CLDN18.2 and have not spread to other parts of the body.
This trial tests a combination of four drugs (liposomal irinotecan, 5-fluorouracil, oxaliplatin, and adebrelimab) given with radiation therapy before surgery for pancreatic cancer that can be surgically removed or is borderline removable. The goal is to shrink the tumor and improve the chances of successful surgery.
This early trial studies whether adding targeted radiation during or around pancreatic surgery is safe and may improve outcomes for people with borderline resectable pancreatic cancer. It is mainly looking at feasibility and safety while treating close to the tumor but not spreading (no metastasis).
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.